Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

This is a phase II, single-arm study to evaluate the efficacy and safety of Afatinib plus chemotherapy as conversion treatment in patients with unresectable EGFR sensitive mutation-positive stage III non-small cell lung cancer.

Trial Details

NCT ID

NCT06709859

Phase

PHASE2

Sponsor

Shandong Public Health Clinical Center

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Afatinib plus chemotherapy as conversion treatment

Locations (sample)

Jinan, Shangdong, China|36.66833,116.99722

Key Eligibility Criteria

Pathologically or cytologically confirmed diagnosis of unresectable Stage III non-small cell lung cancer as judged by the investigator.
Tissue or blood samples tested and confirmed to be positive for EGFR sensitive mutation
ECOG Performance Status of 0-1
At least one measurable lesion according to RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →